Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial

• Main Authors: Mohammadreza Rafati (Author), Hossein Karami (Author), Bita Lashtoo-Aghaee (Author), Bahareh Lashtoo-Aghaee (Author), Mojdeh Dabirian (Author), Razieh Avan (Author)
• Format: Book
• Published: Babol University of Medical Sciences, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Beta-thalassemia major patients typically require chronic transfusion and iron-chelating agents to reduce serum iron overload. Osveral® is an available Iranian brand name of deferasirox used by majority of thalassemic patients. The aim of this study was to compare the efficacy of Osveral...